The SHEP trial (Systolic Hypertension in the Elderly Program) found a nonsignificant trend for a 16% reduction in dementia incidence in the treatment group compared with controls. 85 However, as has been noted in a subsequent reanalyses, 86 a higher drop-out rate in the placebo group may have biased results towards the null hypothesis, particularly in the context of a disease with progressive cognitive decline.
← all excerpts
Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention.
1
—
—